Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Renal Cell 4Urinary Bladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Ovarian Neoplasms 2Kidney Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Urothelial Bladder Carcinoma 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Oligometastatic Prostate Cancer 1Neoplasms 1Neoplasm Metastasis 1Metastatic Urothelial Cancer 1Melanoma 1Esophageal Neoplasms 1Erythrocytosis, Familial, 4 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Merkel Cell 1Breast Neoplasms 1

Interventions

aldesleukin 43Sunitinib 42Cyclophosphamide 30Nivolumab 29pembrolizumab 27Everolimus 27Interferon-alpha 25Bevacizumab 23Sorafenib 22Interleukin-2 20fludarabine phosphate 19Radiotherapy 18Ipilimumab 18Filgrastim 18Axitinib 18Gene Expression Profiling 16Peripheral Blood Stem Cell Transplantation 15Gemcitabine 15cabozantinib 14Radiosurgery 13fludarabine 11Doxorubicin 11Carboplatin 11Blood Specimen Collection 11temsirolimus 10atezolizumab 9Immunohistochemistry 9Etoposide 9Chemotherapy, Adjuvant 9sargramostim 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Kidney Neoplasms × zimberelimab × Genitourinary × Clear all
NCT05536141 2026-06-01

ARC-20

Arcus Biosciences, Inc.

Phase 1 Recruiting
362 enrolled
Genitourinary

Erythrocytosis, Familial, 4, Carcinoma, Renal Cell, Kidney Neoplasms

NCT07397611 2026-03-20

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

Dana-Farber Cancer Institute

Phase 2 Recruiting
32 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡